In late 2014, the PARP inhibitor Olaparib was approved to treat ovarian cancer with BRCA mutations. Since then, research in the field of PARP has received extensive attention, especially in […]
B Cell Receptor (BCR) signaling pathway overview BCR is a transmembrane protein complex that controls B cell maturation, survival, apoptosis, and the production of plasma cell antibodies starting from the […]
Overview of cancer immunotherapy The most widely studied cancer immunotherapies are PD-1/PD-L1 immune checkpoint inhibitors and chimeric antigen receptor-T cell (CAR-T) therapy. With the expanded clinical applications, some defects of […]
Small nucleic acid-based drugs, namely oligonucleotide drugs, are short-chain nucleic acids consisting of dozens of nucleotides in series. At present, most oligonucleotide drugs are obtained through solid-phase chemical synthesis by […]
COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is a betacoronavirus and possesses a positive-sense single-stranded RNA genome that contains 14 open reading frames (ORFs). Two […]
TIGIT is considered to be one of the most promising and potential targets, and a variety of evidence supports that TIGIT plays a key role in limiting the adaptive and […]
BOC Sciences provides varieties of fluorescent-labeled products and services to assist research in related fields.
Structure and function of mesothelin The MSLN gene is located in chromosome 16p13. It contains 17 exons, with a cDNA length of about 2138bp, has a 1884-bp open reading frame, […]
BOC Sciences has directed sincere efforts toward the R&D of small-molecule inhibitors (inhibitors, agonists, and modulators), which greatly free researchers from material outsourcing and selection workload.
Messenger RNA (mRNA) was first discovered in the 1960s, but its instability and immunogenicity have severely hindered the development of mRNA therapy. To solve this problem, researchers have contrived several […]